Noradrenergic α₁ Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial

Thomas F. Newton*, Richard De La Garza II, Gregory Brown, Thomas R. Kosten, James J. Mahoney III, Colin N. Haile

Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States of America

Abstract

Background: Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic α₁ receptor antagonist doxazosin on the positive subjective effects of cocaine.

Methods: Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin, with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with placebo saline randomly interspersed to maintain the blind.

Results: Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of “high”, “stimulated”, “like cocaine”, “desire cocaine”, “any drug effect”, and “likely to use cocaine if had access” (p<.001). Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of “stimulated”, “like cocaine”, and “likely to use cocaine if had access” (p<.05). There were trends for doxazosin to reduce ratings of “stimulated”, “desire cocaine”, and “likely to use cocaine if had access” (p<.10).

Conclusions: Medications that block noradrenergic α₁ receptors, such as doxazosin, may be useful as treatments for cocaine dependence, and should be evaluated further.

Trial Registration: Clinicaltrials.gov NCT01062945

Citation: Newton TF, De La Garza R II, Brown G, Kosten TR, Mahoney JJ III, et al. (2012) Noradrenergic α₁ Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial. PLoS ONE 7(2): e30854. doi:10.1371/journal.pone.0030854

Editor: Bernard Le Foll, Centre for Addiction and Mental Health, Canada

Received September 7, 2011; Accepted December 22, 2011; Published February 3, 2012

Copyright: © 2012 Newton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the National Institutes of Health, P50 DA18197 and M01 RR00188. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: tnewton@bcm.edu

Introduction

A great deal of research aimed at developing treatments for cocaine dependence has focused on agents that directly or indirectly alter functioning of dopaminergic systems, as dopamine (DA) is known to play an important role in mediating cocaine’s reinforcing effects [1]. Progress has been limited, however, as DA antagonists are aversive and non-specifically disrupt behavior [2]. Most direct DA agonists have proven ineffective as treatments for cocaine dependence [3], and indirect DA agonists such as amphetamine or methamphetamine, while effective for reducing cocaine use [4,5], have substantial abuse liability that limits their utility [6].

Genetic and pharmacological evidence has implicated noradrenergic mechanisms in mediating the effects of cocaine and other stimulants [7]. For example, animals which do not express the noradrenergic α₁ receptor (α₁R) are insensitive to the locomotor activating effects of cocaine and amphetamine [8,9], and treatment with the noradrenergic α₁R antagonist prazosin blocks both cocaine-induced locomotor activation [10,11] and cocaine-induced reinstatement of extinguished cocaine self-administration in rats [12].

Prazosin is the prototypical α₁R antagonist. Prazosin has an elimination half-life of 2-3 hours in humans [13], and this limits its potential clinical utility because most patients cannot reliably adhere to dosing regimens that require dosing throughout the day.
Doxazosin is a newer $\alpha_1$R antagonist with an elimination half-life of 22 hours in humans [14], allowing once-daily dosing. Although early reports indicated that doxazosin had poor brain penetration [15,16], the side-effects of doxazosin, which include fatigue, dizziness, and somnolence, suggest that doxazosin acts centrally.

We assessed the impact of doxazosin treatment on cocaine’s effects using a double-blind, placebo-controlled, within-subjects design in non-treatment-seeking, cocaine-dependent volunteers. We hypothesized that doxazosin treatment would attenuate the subjective effects of cocaine.

**Materials and Methods**

**Participants**

Non-treatment-seeking, cocaine-dependent participants were recruited through advertisements and were paid for their participation. They received $50 per day for inpatient components of the study and received a $100 completion bonus. All participants met DMS-IV criteria for cocaine dependence, were between 18 and 55 years old, had a history of using cocaine by the smoked or IV route, and normal laboratory evaluation, ECG, and EEG.

---

**Figure 1. CONSORT Flowchart.** Participant flowchart. doi:10.1371/journal.pone.0030854.g001
Assessments
and all participants gave informed consent. Concomitant use of psychotropic medications or medications affecting blood pressure was not allowed. This study was approved by the institutional review board of the Baylor College of Medicine. Eligibility criteria included a history of use of cocaine, or the presence of any other axis I psychiatric disorder. Serious medical conditions such as heart disease, AIDS, and asthma were also exclusionary. Inability to detect effects of cocaine, or the presence of any other medical condition that could affect cardiovascular or subjective measures was also exclusionary. Concomitant use of psychotropic medications or medications affecting blood pressure was not allowed. This study was approved by the institutional review board of the Baylor College of Medicine and all participants gave informed consent.

**Assessments**

Clinical diagnosis was determined using the MINI [17]. Mood was assessed using the Beck Depression Inventory [18]. Heart rate and blood pressure were measured frequently throughout the study and at several time points following cocaine dosing. Subjective effects of cocaine were measured using visual-analogue scales anchored at 0 (no effect) and 100 (most ever). Ratings were obtained prior to cocaine dosing and at 5 min intervals until 55 min after dosing. Heart rate and blood pressure measures were also collected at the same time points.

**Medications**

Doxazosin 1 mg tablets were purchased commercially from Green Park Pharmacy, Houston TX. Doxazosin was over-encapsulated to mask study medication treatment and encapsulated placebo lactose served as the control. Sterile cocaine HCl for human use was provided by NIDA’s medication supply program by RTI International, Research Triangle Park, NC. Sterile saline was used to dilute the cocaine to the desired concentration and also served as the placebo for cocaine.

**Study Design**

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1. The study employed a within-subjects, double-blind, placebo-controlled design. The order in which participants received doxazosin and placebo was counterbalanced across participants. At least 2 weeks separated study episodes to allow medication wash-out. After screening to assure that participants met inclusion and exclusion criteria, participants were enrolled and housed on the Research Commons of the Michael E. DeBakey VA Medical Center. Participants were monitored closely while inpatient and intermittent UAs were performed to ensure that participants remained abstinent for substances not administered as part of the protocol. Participants were discharged from the hospital between the study episodes. Study medication was started at one capsule per day in the morning and increased by one capsule every three days until participants reached four capsules per day. Resting and orthostatic blood pressure measurements were monitored frequently, as doxazosin can cause hypotension, especially after increases in the dose.

**Cocaine Dosing**

When participants reached 4 mg doxazosin/placebo/d (Day 10 of study medication treatment), participants received cocaine (20 and 40 mg, IV) in ascending order with a dose of saline randomly interspersed to maintain the blind. Two of the three doses were given in the morning, separated by 1 h. The third dose was given in the afternoon, several hours after the previous dose. The three doses were sufficiently separated in time to allow effects to completely dissipate between doses [19]. Participants were monitored and discharged from the hospital when stable, generally after 6–8 h.

**Outcomes**

The primary outcome was the impact of doxazosin treatment on the cardiovascular and subjective effects of cocaine. We also assessed the tolerability of doxazosin treatment alone in this population, with particular attention to effects of doxazosin treatment on blood pressure. We planned on enrolling 15 participants with the goal of obtaining at least 10 completers.

**Table 1.** Demographic Characteristics.

|                | Cocaine Users (N = 13) |
|----------------|------------------------|
| Gender (N)     |                        |
| Male           | 12 (92%)               |
| Female         | 1 (8%)                 |
| Ethnicity (N)  |                        |
| Caucasian      | 3 (23%)                |
| Hispanic       | 1 (8%)                 |
| African American| 9 (69%)               |
| Age (yrs)      | 44.31 ± 4.63           |
| Education (yrs)| 12.46 ± 1.81          |
| Nicotine Use   | 10 (77%)               |
| Cocaine Use    |                        |
| Years of use   | 18.23 ± 5.55           |
| Number of days used last in last 30 days | 15.85 ± 7.87 |
| Grams/day      | 1.30 ± 0.76            |
| Route of Admin |                        |
| Smoked         | 13 (100%)              |

Data in tables reflect mean ± S. D.

doi:10.1371/journal.pone.0030854.t001

doi:10.1371/journal.pone.0030854.t002

|                | Baseline | 1 mg | 2 mg | 3 mg | 4 mg |
|----------------|----------|------|------|------|------|
| Heart Rate     | 70.15 ± 12.37 | 75.39 ± 13.05 | 79.38 ± 10.28 | 83.08 ± 14.87 | 83.08 ± 10.85 |
| Systolic BP    | 121.92 ± 9.31 | 124.39 ± 7.18 | 118.39 ± 11.91 | 121.92 ± 10.14 | 124.17 ± 12.21 |
| Diastolic BL   | 79.54 ± 7.51 | 76.92 ± 8.08 | 73.84 ± 9.79 | 77.69 ± 9.07 | 72.08 ± 9.86 |

Cardiovascular measures taken following 3 days of treatment with 1, 2, 3 mg/d of doxazosin and following 1 day of treatment with 4 mg doxazosin. None of the values differed from baseline (p > .05).

doi:10.1371/journal.pone.0030854.t002
Statistical Analysis

For subjective effects measures, the area under to time-effect curve (AUC) was calculated using the trapezoidal rule [20]. For both morning cocaine doses, ratings collected 15 min prior to the first cocaine dose were used as baseline. For the afternoon dose, ratings collected 15 min prior to the afternoon cocaine dose were used as baseline. A two-way repeated measures analysis of variance (ANOVA) was used to analyze effects of doxazosin (0 and 4 mg) on the subjective effects measured following cocaine at three dose levels (0, 20, 40 mg). When main effects were significant, we conducted pairwise multiple comparisons using the Holm-Sidak method so long as the overall significance level was \( p < 0.05 \). For cardiovascular measures following cocaine dosing, repeated measures ANOVA were calculated, with time (pre-dose to 55 min after cocaine dose) being the repeated measure. We used a repeated measures analysis for cardiovascular measures rather than using the AUC approach because the peak values (e.g., of heart rate and blood pressure) reflect the maximum physiological effects of cocaine and we wanted to document how doxazosin impacted this. We also measured change in cardiovascular measures following study medication dosing at 8 am by comparing cardiovascular measures taken at 9 am to those taken prior to dosing at 7:30 am using a repeated measures ANOVA. The data were tested for normality using the Shapiro-Wilk normality test, and for equal variance using the Levene median test. Statistics were calculated using Sigmaplot version 12 (Systat Software, Inc, San Jose, CA).

Results

The numbers of participants screened, randomized, and the sample analyzed are shown in Figure 1. Participants’ demographic and drug use characteristics are shown in Table 1. Participants were middle-aged and used cocaine on average for more than a

### Table 3. Change in heart rate and blood pressure following dosing.

|                | Doxazosin 1 mg | Doxazosin 2 mg | Doxazosin 3 mg | Doxazosin 4 mg |
|----------------|---------------|---------------|---------------|---------------|
| Heart Rate     | .61 ± 10.1    | -2.92 ± 13.6  | 6.08 ± 12.01  | 5.08 ± 9.81   |
| Systolic BP    | -.15 ± 8.25   | -1.46 ± 8.38  | -2.15 ± 9.22  | -4.66 ± 8.40  |
| Diastolic BL   | -1.38 ± 4.33  | .69 ± 8.62    | .85 ± 12.16   | -1.15 ± 10.53 |

Placebo

|                |            |               |               |               |
|----------------|------------|---------------|---------------|---------------|
| Heart Rate     | .23 ± 9.43 | 2.54 ± 15.40  | 1.61 ± 13.20  | -2.15 ± 9.71  |
| Systolic BP    | -.46 ± 1035| 1.15 ± 8.38   | -1.38 ± 8.93  | -2.31 ± 12.24 |
| Diastolic BL   | -1.08 ± 7.67| -1.85 ± 5.86  | -2.69 ± 6.72  | -1.38 ± 8.98  |

Study medication was dosed at 8am and values represent change (9am minus 7:30am) in heart rate and blood pressure. Measures recorded during treatment with doxazosin did not differ from those recorded during treatment with placebo and no dose differed from another dose (\( p > 0.10 \)).

doi:10.1371/journal.pone.0030854.t003

![Figure 2. Heart rate and blood pressure following cocaine dosing.](image)

Cardiovascular measures are plotted as change from baseline following cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. * \( p < 0.05 \), + \( p < 0.10 \).

doi:10.1371/journal.pone.0030854.g002
decade. Most used alcohol and marijuana frequently, though none met criteria for dependence. Most smoked cigarettes and met criteria for nicotine dependence.

Doxazosin treatment was well tolerated and no participant was discontinued from the study due to side-effects. No participant spontaneously reported sedation, a known side effect of doxazosin, though we did not rate sedation or query participants. Heart rate and blood pressure were not significantly affected. Heart rate and blood pressure measures on the final day of treatment with each doxazosin dose are shown in Table 2. There were no significant differences between measures taken during placebo and doxazosin treatment (p>.10). Change in heart rate and blood pressure following study medication dosing on the first day of treatment with each dose of study medication, when the largest effects would be expected, are shown in Table 3. Doxazosin and placebo both produced minimal changes in blood pressure measured following...
study medication dosing on the first day of treatment with each
dose of study medication (p>.10).

Doxazosin had trend-level effects on systolic blood pressure
following cocaine dosing (p<.09) but did not significantly affect
diastolic blood pressure or heart rate and there were no
statistically significant interactions between cocaine dose and
cardiovascular measures. Cardiovascular measures over the
55 min following cocaine dosing are shown in Figures 2, 3, 4.

Figure 5. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as “not effects” and 100 anchored as “most ever”. ANOVA showed that there were significant effects (p<.05) of medication on ratings of “Stimulated”, “Like Cocaine”, “Desire Cocaine”, and “Likely to Use Cocaine”. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p<.05, + p<.10.
doi:10.1371/journal.pone.0030854.g005

Figure 6. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as “not effects” and 100 anchored as “most ever”. ANOVA showed that there were significant effects (p<.05) of medication on ratings of “Stimulated”, “Like Cocaine”, “Desire Cocaine”, and “Likely to Use Cocaine”. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p<.05, + p<.10.
doi:10.1371/journal.pone.0030854.g006
Cocaine produced increases in ratings for most subjective effects, including “high”, “any drug effect”, “stimulated”, and “good effects” (p<.001). There were significant effects of study drug treatment for ratings of “stimulated” (F = 7.41, p = .019), “like” (F = 5.17, p = .042), and “desire cocaine” (F = 5.47, p = .037), and “likely to use cocaine” (F = 5.57, p = .036). For each of these variables, the assumptions regarding normal distributions of data were met. For all but “like” the equal variance assumption was met as well. These are shown in figures 5, 6, 7, 8. Post hoc analysis (using the Holm-Sidak method) showed that doxazosin treatment reduced effects the effects of 20 mg cocaine on ratings of “stimulated” (t = 2.20, p = .035), “like” (t = 2.16, p = .037), and “likely to use cocaine if had access” (t = 2.29, p = .028). These analyses showed that doxazosin
treatment produced trend-level reductions in the effects of 40 mg cocaine on ratings of “stimulated” ($t = 1.78, p = .083$), “desire cocaine” ($t = 1.96, p = .059$), and “likely to use cocaine if had access” ($t = 1.78, p = .083$). Doxazosin treatment did not have significant effects on ratings of “high”, “any drug effects” or other subjective effects ratings (not shown).

**Discussion**

Doxazosin treatment was well tolerated, as was expected from earlier studies in other normotensive populations [21]. Doxazosin treatment had very modest effects on heart rate and blood pressure. The blood pressure effects of cocaine are likely mediated by sympathetic outflow and by effects of epinephrine and NE on peripheral vasculature and the observed effects of doxazosin on the cardiovascular effects of cocaine are consistent with this.

Doxazosin treatment significantly attenuated several of the positive subjective effects produced by cocaine, including ratings of “stimulated” and “like cocaine”, though the results for like should be interpreted with caution due to statistical limitations. Doxazosin also attenuated ratings of “likely to use” an index of craving. The magnitude of the effect was substantial for some of the variables (for example, the effect size $d$ for reductions in “stimulated” during doxazosin treatment following administration of 20 mg cocaine was 0.84, which is considered large [22]).

The usual dose of doxazosin for the treatment of hypertension is 8–16 mg/d, which is several-fold higher than the dose we tested in this study, 4 mg/d. Further, though doxazosin 4 mg substantially attenuated many of the effects produced by 20 mg cocaine, this dose of doxazosin reduced the effects produced by 40 mg cocaine to a more modest extent. Higher doses of doxazosin would be expected to have a greater impact on the effects produced by a wider range of cocaine doses, including perhaps doses abused by cocaine users. These doses are thought to be in the 50 to 100 mg range, though there are no good data to base this estimate on. Nevertheless, that doxazosin antagonism of cocaine’s was surmounted by the higher cocaine dose suggests a pharmacological dose-effect function and likely higher doses of doxazosin are needed for more complete antagonism.

These data are very much in keeping with data reported in rats by Zhang and colleagues [12], who found that prazosin pretreatment dose-dependently attenuated cocaine-induced reinstatement of extinguished cocaine-seeking behavior. The “reinstatement model” is frequently put forward as a model for craving induced by drug, stress, or other factors [23].

The report by Zhang and colleagues is somewhat at odds with older data reported by Woolverton [24] who found that prazosin did not alter responding maintained by cocaine. Prazosin treatment thus produced differential effects on cocaine reinstatement compared to reinforcing effects of cocaine. Consistent with this dissociation, we found that doxazosin treatment reduced indices reflecting desirability of cocaine, such as “like” and “likely to use cocaine with access”, without affecting indices reflecting euphoria, such as “high”. Euphoric effects are thought to relate to reinforcing effects [25,26], though they need not necessarily do so [27].

The dampening effects of doxazosin on ratings of “stimulated” that we observed may reflect doxazosin’s specific effects on noradrenergic neurotransmission. Cocaine inhibits the reuptake of NE with nearly the same potency that it inhibits the reuptake of DA [28]. The present data complement earlier preclinical research [7], and underscore the importance of noradrenergic mechanisms in mediating many of cocaine’s effects.

It is not known precisely how doxazosin treatment modulates the subjective effects of cocaine. Noradrenergic $\alpha_1$Rs are expressed widely throughout the brain, most notably in the striatum and the prefrontal cortex (PFC) [29]. Acting within the PFC, doxazosin could block noradrenergically mediated release of DA in the fronto-accumbens circuit, blunting accumbal activation [30].

These data demonstrate, for the first time in humans, that an $\alpha_1$R receptor antagonist can attenuate several of the effects of cocaine. These findings parallel closely those previously reported in preclinical research, increasing confidence in the findings. Nevertheless, the sample size was relatively small and replication is needed. The dose of doxazosin used was at the low end of the therapeutic window, and higher doses should be tested. Other medications affecting adrenergic activation are used successfully in the treatment of hypertension [31] (also a noradrenergically-mediated phenomenon) and these might be assessed as possible treatments for cocaine dependence as well. Examples include other preparations of doxazosin, such as extended release doxazosin XL, $\alpha_2$R receptor agonists such as lofexidine, and other classes of antihypertensives, such angiotensin converting enzyme inhibitors (e.g. perindopril).

**Supporting Information**

**Protocol S1** Trial Protocol. (DOC)

**Checklist S1** CONSORT Checklist. (DOC)

**Acknowledgments**

We would like to acknowledge the expert assistance of the BCM General Clinical Research Center nursing staff.

**Author Contributions**

Conceived and designed the experiments: TN RDG TRK JJM CNH. Performed the experiments: TN RDG GB JJM CNH. Analyzed the data: TN RDG. Contributed reagents/materials/analysis tools: TN RDG. Wrote the paper: TN RDG CH.

**References**

1. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40: 191–225.

2. Woolverton VL, Balster RL (1981) Effects of antipsychotic compounds in rhesus monkeys given a choice between cocaine and food. Drug Alcohol Depend 8: 69–78.

3. Soares BG, Lima MS, Reisser AA, Farrell M (2001) Dopamine agonists for cocaine dependence (Cochrane Review). Cochrane Database Syst Rev 4.

4. Grabowski J, Rhodes H, Stotts A, Cowan K, Kopecky C, et al. (2004) Agonist-like or antagonist-like treatment for cocaine dependence (Cochrane Review). Cochrane Database Syst Rev 4.

5. Mooney ME, Herrin DV, Schmutz JM, Moukaddam N, Green CE, et al. (2009) Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 101: 34–41.

6. Jasinski DR (1991) History of abuse liability testing in humans. British Journal of Addiction 86: 1559-1562.

7. Weinschenker D, Schroeder JP (2007) There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32: 1433–1451.

8. Drouin C, Darracq L, Traverso F, Blanc G, Glosinski J, et al. (2002) Alpha1-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22: 2873–2884.

9. Darracq L, Blanc G, Glosinski J, Tassin J-P (1998) Importance of the Noradrenaline-Dopamine Coupling in the Locomotor Activating Effects of D-Amphetamine. J Neurosci 18: 2729–2739.

10. Drouin C, Blanc G, Villegier AS, Glosinski J, Tassin JP (2002) Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preweaning conditions and pharmacological characteristics. Synapse 43: 51–61.
11. Snoddy AM, Tessel RE (1985) Prazosin: effect on psychomotor-stimulant cues and locomotor activity in mice. Eur J Pharmacol 116: 221–228.

12. Zhang XY, Kosten TA (2005) Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry 57: 1202–1204.

13. Jaillon P (1980) Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 5: 365–376.

14. Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL (1982) A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK-33274) in normotensive subjects. Br J Clin Pharmacol 13: 699–703.

15. Prys-Roberts C, Fardown JR (2002) Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 26: 1037–1042.

16. Guo TZ, Tinklenberg J, Oliker R, Maze M (1991) Central alpha 1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist. Anesthesiology 75: 252–256.

17. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20: 22–33; quiz 34–57.

18. Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67: 588–597.

19. Newton TF, De La Garza R, 2nd, Kalechstein AD, Nestor L (2005) Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav 82: 90–97.

20. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6: 539–546.

21. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87: 192–200.

22. Cohen J (1988) Statistical Power Analysis for the Behavioral Science. Hillsdale, N.J.: L. Erlbaum Associates.

23. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3–20.

24. Woolverton WL (1987) Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. Pharmacol Biochem Behav 26: 835–839.

25. Fisman MV (1989) Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. NIDA Res Monogr 92: 211–230.

26. Fisman MV, Felin RW (1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86: 1563–1570.

27. Haney M, Speelman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199: 403–419.

28. Rothman RB, Blough BE, Baumann MH (2002) Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann N Y Acad Sci 965: 169–126.

29. Morrison JH, Molliver ME, Grzanna R, Coyle JT (1981) The intra-cortical trajectory of the coeruleo-cortical projection in the rat: a tangentially organized cortical afferent. Neuroscience 6: 139–158.

30. Schroeder JP, Cooper DA, Schank JR, Lyle MA, Gaval-Cruz M, et al. (2010) Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 35: 2440–2449.

31. Waeber B, Fröhlich F, Ruilope LM (2009) Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 69: 1761–1776.